Basel, April 6, 2024 – Novartis today announced new data demonstrating the early addition of twice-yearly* Leqvio® (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), including those with a history of an ASCVD-related event, who could not reach their goal on statin therapy alone1. The late-breaking data were presented at the 2024 American College of Cardiology’s Annual Scientific Session & Expo and simultaneously published in the Journal of the American College of Cardiology.
Author: Ken Dropiewski
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
— Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels — — Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) –
V-Wave Announces Late-Breaking Primary Results from Pivotal, Double-Blind, Randomized, Controlled RELIEVE-HF Trial of the Ventura® Interatrial Shunt Showing Reduced Clinical Events in Advanced Heart Failure Patients with Reduced Left Ventricular Ejection Fraction
Results presented at ACC.24 showed that overall neutral results were due to directionally opposite effects in patients with reduced vs. preserved left ventricular ejection fraction Heart failure patients with reduced ejection (HFrEF) had 45% fewer adverse cardiovascular events, whereas…
Johnson & Johnson to Acquire Shockwave Medical
April 05, 2024 06:31 AM Eastern Daylight Time NEW BRUNSWICK, N.J. & SANTA CLARA, Calif.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 […]
Osso VR Expands Cardiology Training through ACC Collaboration
SAN FRANCISCO, April 4, 2024 – Osso VR, the leader in immersive procedural training, announces the release of a co-developed curriculum with the American College of Cardiology (ACC). This collaboration expands Osso VR’s presence in the cardiovascular sector. With the integration of Osso VR’s immersive technology and the expertise of […]
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO): “During our fiscal third quarter, we took another significant step in our transformation with the divestiture of our PICC and Midline product portfolios, further strengthening our balance sheet and providing us with an opportunity to enhance our focus on the growth of our Med […]
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States Food and Drug Administration (FDA) has cleared the AlphaVac F1885 System for […]
Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces a strategic partnership with Navierre, an innovative digital health technology platform which revolutionizes how patients access healthcare and serves as a true health companion for every stage from birth to the golden years with a robust care […]
Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions
Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions
Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24
Clinical and real-world evidence presentations highlight how the Company is transforming care for patients who are fighting some of the most common and devastating cardiovascular diseases NEW BRUNSWICK, N.J., April 4, 2024 /PRNewswire/ — Johnson & Johnson announced today that clinical…
Recent
Solaris Endovascular Receives FDA Breakthrough Device Designation for Solaris DE™, a new Drug-Eluting Covered Stent
Embolization, Inc., Presents Novel Polymer-Based Coil at GEST, Booth No. 403
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
Popular
- No commented posts yet